Get human insights into your preclinical drug development
KRAS remains one of the most notorious oncogenes in cancer—frequently mutated, clinically significant, and historically “undruggable.” But that’s changing.
In our latest study, we tested eight KRAS inhibitors across a diverse panel of over 20 patient-derived organoids (PDOs) from colorectal, pancreatic, and lung cancers—each harboring different KRAS mutations.
What you'll learn:
- How PDOs reflect real-world tumor diversity across CRC, PDAC, and NSCLC
- Results from testing 8 KRAS inhibitors across 20+ organoid models
- Why Tipifarnib shows broad activity—and how resistance in KRASG12C mutants can be overcome
- The role of EGFR inhibition in boosting KRAS inhibitor response
Looking to begin your KRASi Organoid Screen?
Share your screening parameters and get an instant quote
